Review article: Multimodality treatment of liver metastases increases suitability for surgical treatment

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 2, 2007, Pages 161-169

  De Jong, K P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LIVER TUMOR; MULTIMODALITY CANCER THERAPY; PORTAL VEIN BLOOD FLOW; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TUMOR LOCALIZATION;

ADENOCARCINOMA; CATHETER ABLATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS;

EID: 36849052883     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03484.x     Document Type: Conference Paper

References (57)

1. Lortat-Jacob IL, Robert HG. Hepatectomie droite reglée. Presse Med 1952 60 : 549 51.
2. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005 16 : 779 90.
3. Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999 86 : 784 8.
4. Kokudo N, Tada K, Seki M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001 34 : 267 72.
5. Madoff DC, Abdalla EK, Gupta S, et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005 1 (2 Pt 1 215 25.
6. de Jong KP, Slooff MJH, de Vries EGE, Brouwers MAM, Terpstra OT. Effect of partial liver resection on tumour growth. J Hepatol 1996 25 : 109 21.
7. de Jong KP, Alting von Geusau B, Rottier CA, et al. Serum response of hepatocyte growth factor, insulin-like growth factor-I, interleukin-6, and acute phase proteins in patients with colorectal liver metastases treated with partial hepatectomy or cryosurgery. J Hepatol 2001 34 : 422 7.
8. de Jong KP, Hoedemakers RMJ, Fidler V, et al. Portal and systemic serum growth factor and acute phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor. Scand J Gastroenterol 2004 39 : 1141 8.
9. Drixler TA, Vogten MJ, Ritchie ED, et al. Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg 2002 236 : 703 11.
10. Rocheleau B, Ethier C, Houle R, Huet PM, Bilodeau M. Hepatic artery buffer response following left portal vein ligation: its role in liver tissue homeostasis. Am J Physiol 1999 277 (5 Pt 1 G1000 7.
11. Ruers TJ, de Jong KP, IJzermans JN. Radiofrequency for the treatment of liver tumours. Dig Surg 2005 22 : 245 53.
12. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006 141 : 181 90.
13. Stippel DL, Brochhagen HG, Arenja M, Hunkemoller J, Holscher AH, Beckurts KT. Variability of size and shape of necrosis induced by radiofrequency ablation in human livers: a volumetric evaluation. Ann Surg Oncol 2004 11 : 420 5.
14. Khajanchee YS, Streeter D, Swanstrom LL, Hansen PD. A mathematical model for preoperative planning of radiofrequency ablation of hepatic tumors. Surg Endosc 2004 18 : 696 701.
15. Poon RT, Ng KK, Lam CM, et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004 239 : 441 9.
16. Hildebrand P, Leibecke T, Kleemann M, et al. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. Eur J Surg Oncol 2006 32 : 430 4.
17. Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". Cancer 2003 97 : 3027 35.
18. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005 23 : 1358 64.
19. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006 141 : 460 6.
20. van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006 13 : 651 8.
21. Ouellet JF, Pessaux P, Pocard M, Elias D. Transmetastasis curative liver resection immediately following radiofrequency destruction. J Surg Oncol 2002 81 : 108 10.
22. Elias D, Manganas D, Benizri E, et al. The trans-metastasis hepatectomy (through metastases previously ablated with radiofrequency): results of a 13-case study of colorectal cancer. J Surg Oncol 2006 93 : 8 12.
23. Elias D, Manganas D, Benizri E, et al. Trans-metastasis hepatectomy: results of a 21-case study. Eur J Surg Oncol 2006 32 : 213 7.
24. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996 224 : 509 22.
25. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003 7 : 109 15.
26. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005 200 : 845 53.
27. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003 7 : 1034 44.
28. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004 15 : 460 6.
29. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006 243 : 1 7.
30. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006 24 : 2065 72.
31. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. J Clin Oncol 2004 22 14S : 3512.
32. Rougier P, Raoul JL, Van-Laethem JL, et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol 2004 22 14S : 3513.
33. Harari PM, Durland WF, Chinnaiyan P, Hartig GK. Impact of the EGFR inhibitor C225 on wound healing in advanced head & neck cancer patients undergoing neck dissection. Proc Am Soc Clin Oncol 2003 22 : 22, 220.
34. Li WW, Talcott KE, Zhai AW, Kruger EA, Li VW. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care 2005 18 : 491 500.
35. Redaelli CA, Semela D, Carrick FE, et al. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 2004 40 : 305 12.
36. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005 91 : 173 80.
37. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005 23 : 4853 5.
38. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of hepatic metastases. Surgery 1988 103 : 278 88.
39. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995 19 : 59 71.
40. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999 230 : 309 18.
41. Brister SJ, de Varennes B, Gordon PH, Sheiner NM, Pym J. Contemporary operative management of pulmonary metastases of colorectal origin. Dis Colon Rectum 1988 31 : 786 92.
42. Goya T, Miyazawa N, Kondo H, Tsuchiya R, Naruke T, Suemasu K. Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 1989 64 : 1418 21.
43. Scheele J, Altendorf-Hofmann A, Stangl R, Gall FP. Pulmonary resection for metastatic colon and upper rectum cancer. Is it useful? Dis Colon Rectum 1990 33 : 745 52.
44. Girard P, Ducreux M, Baldeyrou P, et al. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996 14 : 2047 53.
45. Ike H, Shimada H, Togo S, Yamaguchi S, Ichikawa Y, Tanaka K. Sequential resection of lung metastasis following partial hepatectomy for colorectal cancer. Br J Surg 2002 89 : 1164 8.
46. Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002 124 : 1007 13.
47. Pfannschmidt J, Klode J, Muley T, Dienemann H, Hoffmann H. Nodal involvement at the time of pulmonary metastasectomy: experiences in 245 patients. Ann Thorac Surg 2006 81 : 448 54.
48. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005 12 : 900 9.
49. Koch M, Kienle P, Kastrati D, et al. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer 2006 118 : 3072 7.
50. Koch M, Kienle P, Hinz U, et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 2005 241 : 199 205.
51. Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002 29 : 915 21.
52. Vogel WV, Wiering B, Corstens FH, Ruers TJ, Oyen WJ. Colorectal cancer: the role of PET/CT in recurrence. Cancer Imaging 2005 5 (Spec No A S143 9.
53. Rivoire M, De Cian F, Meeus P, Negrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002 95 : 2283 92.
54. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004 240 : 644 57.
55. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004 15 : 933 9.
56. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005 23 : 9243 9.
57. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/ folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006 13 : 58 65.